Verrica Pharma Reports Exit/Disposal Costs
Ticker: VRCA · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.0 m, $0.7 million, $0.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, divestiture, corporate-action
TL;DR
Verrica Pharma's 8-K: Costs related to exiting or disposing of something are being reported. Details TBD.
AI Summary
Verrica Pharmaceuticals Inc. filed an 8-K on October 1, 2024, to report on cost associated with exit or disposal activities. The filing does not contain specific dollar amounts or details regarding the nature of these costs, but it indicates a formal reporting event related to such activities.
Why It Matters
This filing signals that Verrica Pharmaceuticals is undergoing restructuring or divesting certain assets, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates potential restructuring or divestiture, which carries inherent business risks that are not fully detailed.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- October 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- PA (state) — Principal Executive Offices State
- West Chester (city) — Principal Executive Offices City
FAQ
What specific activities are associated with the exit or disposal costs reported by Verrica Pharmaceuticals?
The filing does not specify the exact nature of the exit or disposal activities, only that costs are associated with them.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 1, 2024.
What is the principal executive office address for Verrica Pharmaceuticals?
The principal executive offices are located at 44 W. Gay St., Suite 400, West Chester, PA 19380.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Verrica Pharmaceuticals' IRS Employer Identification Number?
Verrica Pharmaceuticals' IRS Employer Identification Number is 46-3137900.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-10-01 16:37:53
Key Financial Figures
- $1.0 m — o incur total expenses of approximately $1.0 million, including a one-time charge tota
- $0.7 million — one-time charge totaling approximately $0.7 million in connection with one-time employee te
- $0.3 million — timated deemed loss on vehicle sales of $0.3 million. The Company expects such costs to be t
Filing Documents
- d823075d8k.htm (8-K) — 23KB
- 0001193125-24-230240.txt ( ) — 141KB
- vrca-20241001.xsd (EX-101.SCH) — 3KB
- vrca-20241001_lab.xml (EX-101.LAB) — 18KB
- vrca-20241001_pre.xml (EX-101.PRE) — 11KB
- d823075d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: October 1, 2024 /s/ Ted White Ted White President and Chief Executive Officer